CTRI/2022/10/046397招募中未知
Development of a precision oncology platform (4C-ONCO) that predicts accurate response to CRC and HNSCC biomarkers, through an AI-based multi-layer deep learning approach - 4C-ONCO
BIRAC0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Persons above 18 years of age, diagnosed with HNSCC or CRC, any grade, any stage, chemo-naïve or previously treated and unresponsive to treatment, capable of giving consent
排除标准
- •Persons without HNSCC or CRC or those incapable of giving consent
研究者
相似试验
进行中（未招募）
1 期
An Open-Label, Phase IV Study of Velaglucerase alfa on Bone Related Pathology in Adult, Treatment-Naïve Patients with Type 1 Gaucher DiseaseGaucher DiseaseMedDRA version: 20.0Level: PTClassification code 10075697Term: Gaucher's disease type ISystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2015-001578-17-ITSHIRE HUMAN GENETIC THERAPIES, INC40
进行中（未招募）
1 期
An Open-Label, Phase IV Study of Velaglucerase alfa on Bone Related Pathology in Adult, Treatment-Naïve Patients with Type 1 Gaucher DiseaseMedDRA version: 20.0Level: PTClassification code 10075697Term: Gaucher's disease type ISystem Organ Class: 10010331 - Congenital, familial and genetic disordersGaucher DiseaseEUCTR2015-001578-17-DEShire Human Genetic Therapies, Inc.40
进行中（未招募）
1 期
An Open-Label, Phase IV Study of Velaglucerase alfa on Bone Related Pathology in Adult, Treatment-Naïve Patients with Type 1 Gaucher DiseaseMedDRA version: 20.0Level: PTClassification code 10075697Term: Gaucher's disease type ISystem Organ Class: 10010331 - Congenital, familial and genetic disordersGaucher DiseaseEUCTR2015-001578-17-GBShire Human Genetic Therapies, Inc.19
进行中（未招募）
1 期
An Open-Label, Phase IV Study of Velaglucerase alfa on Bone Related Pathology in Adult, Treatment-Naïve Patients with Type 1 Gaucher DiseaseGaucher DiseaseMedDRA version: 18.1Level: PTClassification code 10075697Term: Gaucher's disease type ISystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2015-001578-17-ESShire Human Genetic Therapies, Inc.21
进行中（未招募）
1 期
China post-marketing surveillance (PMS) study of Aldurazyme®Mucopolysaccharidosis IMedDRA version: 20.1Level: PTClassification code 10056886Term: Mucopolysaccharidosis ISystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2023-001027-16-Outside-EU/EEAGenzyme Europe B. V